US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672923729","title":"Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672923729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672923729?lang=en_us&edition=fundamental","pubTime":"2026-10-04 03:40","pubTimestamp":1791056400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S 120 mg/m every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/03/3374111/0/en/genmab-announces-rinatabart-sesutecan-rina-s-phase-2-rainfol-01-results-demonstrated-durable-and-clinically-meaningful-responses-in-patients-with-platinum-resistant-ovarian-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU2092937221.SGD","BK4080","PROC","ADC","BK4231","LU0310800379.SGD","LU0708994859.HKD","NETL","IE00BGHQF417.EUR","LU2360108059.USD","IE00B3CCJ633.GBP","LU2023250504.SGD","LU1267930573.SGD","LU1917777945.USD","LU1974910355.USD","IE00B2PGVK34.USD","XHB","BK4086","LU2298321311.HKD","LU2041044095.USD","LU0868494617.USD","OC","LU2106854487.HKD","LU0029864427.USD","LU2048586759.USD","ORR","BK4007","LU2023250843.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646482","title":"Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646482","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:00","pubTimestamp":1790175600,"startTime":"0","endTime":"0","summary":"Amgen rebounds to $410.24 as dazodalibep and IMDELLTRA strengthen the pipeline while $418.73 becomes the next technical test.\n","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262182585-stocks-amgen-stock-forecast-pipeline-410-breakout-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","ORR","PBE","TSLG","LU1061106388.HKD","BGSX","AZN","TSLT","TSL","BIB","TSLP","TSLI","LU2242652126.USD","LU0868494617.USD","07766","ELOL","LU2468319806.SGD","TSLQ","AMGN","09766","09366","BBH","TSLL","TSII","07366","TLA","LU1571399168.USD","PJP","IE0009355771.USD","TSDD","TSLZ","BK7095","ORR.AU","TSLY","TEST","LU1983299246.USD","LU2237443549.SGD","TESC","TSLO","IBB","TSYY","IE0002141913.USD","TBXU","TSLR","TSLS","CRSH","TSLW","IBBQ","TESL","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882142","title":"PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882142","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor nave patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366230/37149/en/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-canc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IDNA","BK4585","BK4588","ORR","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108925192","title":"EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle","url":"https://stock-news.laohu8.com/highlight/detail?id=1108925192","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108925192?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:20","pubTimestamp":1789975238,"startTime":"0","endTime":"0","summary":"In the precision-targeted therapy space for non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations (ex20ins) have long been viewed as one of the most difficult-to-treat niche targets...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","IPOS","BK4195","BK4211","ORR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":30,"pageCount":1,"totalSize":118,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}